While it is established that BRG1 is commonly up-regulated in prostate cancer, the full range of molecular pathways impacted by dysregulated BRG1 levels and the contribution of these molecular changes to the atypical phenotype of prostate cancer cells remains unclear. The gene discussed is SMARCA4; the disease is Familial prostate cancer.